Drug intelligence / Profile preview

ethanolamine oleate

Development stage: Approved
Modality: Small Molecules
Administration: Intravenous

Overview

Ethanolamine oleate is a synthetic compound formed from ethanolamine and oleic acid, classified as a mild sclerosing agent. It is primarily used for the treatment of esophageal varices that have recently bled, a life-threatening complication often associated with severe liver disease. The drug acts by causing localized inflammation and subsequent fibrosis within the varices, leading to their obliteration and reducing the risk of further bleeding. Ethanolamine oleate does not address underlying liver pathology but serves as an emergency intervention to control acute hemorrhage from esophageal varices[1][2][3][4]. Its mechanism involves direct endothelial damage at the injection site, promoting thrombosis and sclerosis of targeted blood vessels.

Brand names: Ethamolin
Other names: monoethanolamine oleate

Beyond the preview

Go deeper on ethanolamine oleate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethanolamine oleate.

Explore the full profile